https://www.selleckchem.com/pr....oducts/CI-1040-(PD18
presenting with vital, symptomless, carious dentin lesions in primary teeth. There is evidence in favor of PMCs for restoring multisurface carious lesions in primary molars. Esketamine nasal spray received approval for treatment-resistant depression in March 2019. Using the FDA Adverse Event Reporting System (FAERS) database (March 2019-March 202, we analysed esketamine-related adverse events (AEs) to detect and characterize relevant safety signals. We used the consolidated case/non-case approach to estimate the reporting o
Like
Comment
Share
